C. Marth

New insights into p53 regulation and gene therapy for cancer.

M. Widschwendter, C. Marth, G. Daxenbichler, 2000, Biochemical pharmacology.

Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.

O. Dapunt, D. Fuchs, M. Widschwendter, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells.

H. Zwierzina, P. Klingler, F. Offner, 1995, Cytokine.

Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer.

C. Marth, B. Eibl, D. Niederwieser, 1996, Blood.

The game-changing impact of POLE mutations in oncology-a review from a gynecologic oncology perspective.

J. Kögl, C. Marth, A. Zeimet, 2024, Frontiers in oncology.

High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.

O. Dapunt, M. Widschwendter, C. Marth, 1997, British Journal of Cancer.

Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1.

P. Klingler, C. Marth, F. Offner, 1996, The American journal of pathology.